Oncologist/Hematologist | ⚜️ @LSUHS & @CreightonIMPhx Alum | 🎸 N.E.M 🖤 Dream On ✨ | Views mine
Joined January 2010
- Tweets2.2K
- Following2.5K
- Followers1.3K
- Likes2.9K
Pinned Tweet
I am overjoyed to share that My Piece "A letter to my muse" got recognized in the "Best of ASCO Connection Blogs 2021-2022" magazine that will be available in print at the ASCO22 annual meeting.
digitaledition.qwinc.com/pub…
Dawood Findakly, MD, FACP retweeted
Dostarlimab (IV q3 wks, 9 cycles) is now @FDA ✅ for locally advanced (Stg II/III) MSI-H/dMMR rectal cancer off Ph II AZUR-1 study:
- 71% got IO alone (no additional Rx)
- Clinical CR for 12 mos: 47% (no progression at 26.3mos median f/u)
- Surgery/Chemo free option!
#gism
@AndreaCercek 🤩announced at #ESMOGI2026 phase 2 AZUR-1 will be presented at @myESMO #ESMO2026 which was created to validate her original single center Dostarlimab data in #rectal #cancer. Looking forward to the results! #CancerResearch @GSK_US @OncoAlert
Periprocedure anticoagulation management algorithm.
acforum.org/web/scripts/view…
#MedTwitter #Anticoagulation #Periprocedural #DOAC #Warfarin #VTE #Thrombosis #ACForum #MedEd
Dawood Findakly, MD, FACP retweeted
Here is the one pager/summary of EXCALIBER-RRMM trial that we touched on with @SagarLonialMD! This study led to the accelerated approval of Iberdomide + Dara & Dex in 2L and beyond for #MultipleMyeloma 👇👇
@OncUpdates @OncoAlert #mmsm #HemeTwitter #MedX
Iberdomide (CELMoD) + Dara is now @US_FDA ✅ in 2L and beyond for MM off EXCALIBER-RRMM! We 🗣️ this trial, findings (MRD), and AEs w/ @SagarLonialMD
Full 🗣️:
⭐️ oncbrothers.com/excaliber-rr…
⭐️Also on “Oncology Brothers” podcast
@OncUpdates #OncTwitter #HemeTwitter
Dawood Findakly, MD, FACP retweeted
Proud to have contributed to newly published 2026 @ASH_hematology Guidelines for Myelofibrosis!
10 evidence-based recs spanning molecular testing, JAK inhibitors, anemia & transplant.
📄 doi.org/10.1182/bloodadvance…
#Myelofibrosis #MPN #Hematology #ASHGuidelines #BloodAdvances
Dawood Findakly, MD, FACP retweeted
Free Access: My 2026 update on diagnosis, risk stratification, treatment, and prognosis of multiple myeloma.
Link: onlinelibrary.wiley.com/doi/… @AjHematology
Algorithms. 10 Tables!
Bookmark!
Had a fantastic time at the LSU Shreveport Heme/Onc Alumni & Fellows Career Forum! It was wonderful connecting with such an incredible team, sharing experiences, and discussing the future of our field. 🩺 #LSUHealth @LSUHS @PoornimaRamadas @SChenspeaks @DeeptiKantamani
Dawood Findakly, MD, FACP retweeted
Here are the treatment algorithms we have used during our DLBCL, FL, and Mantle Cell Lymphoma discussions with @mshadman & @DrJFriedberg
#Lymphoma #OncTwitter #MedTwitter @OncUpdates @OncoAlert
Treatment Algorithm discussion on Diffuse Large B-Cell lymphoma (DLBCL) with @mshadman
✅ Upfront Rx
✅ Sequencing
✅ Side effects/management
Full 🗣️:
⭐️ oncbrothers.com/dlbcl-algo-2…
⭐️ Also on “Oncology Brothers” podcast
#OncTwitter #HemeTwitter @OncUpdates @OncoAlert
Dawood Findakly, MD, FACP retweeted
Treatment Algorithm discussion on Follicular and Mantle cell Lymphoma with @DrJFriedberg
✅ Work-up
✅ Upfront Rx & maintenance
✅ Sequencing
Full 🗣️:
⭐️ oncbrothers.com/follicular-m…
⭐️ Also on “Oncology Brothers” podcast
#OncTwitter #HemeTwitter @OncUpdates @WilmotCancer
Dawood Findakly, MD, FACP retweeted
Based off LITESPARK-011: Belzutifan + Lenvatinib is now @FDA ✅ in 2L RCC after IO exposure:
PhIII: Bel + Len vs. Cabo
- mPFS 14.6mos vs. 10.7mos (HR: 0.74)
- mOS 33.7mos vs. 28.6mos (HR: 0.85, p=0.061).
- AEs: 72% vs. 66% w/ Gr ≥ 3
#OncTwitter #gusm @OncUpdates
Nice Schematic overview on Plasma cell disorders.
#mmsm #OncTwitter #HemeTwitter #MedX #IMWG
link.springer.com/article/10…
Dawood Findakly, MD, FACP retweeted
Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer
Excellent review👇
annalsofoncology.org/article…
Dawood Findakly, MD, FACP retweeted
Two Decades of NPM1-Mutated Acute Myeloid Leukemia: From Molecular Insights to Clinical Decision-Making mdpi.com/4091650 #mdpicancers via @Cancers_MDPI #leusm
Dawood Findakly, MD, FACP retweeted
Highlights from #WCLC26 #CommunityOncology:
NSCLC
1. #ADAURA Update Adj mEGFR
2. #PAPILLON 1L EGFR Ex20
3. #DESTINYLung04 1L mHER2
4. #ARROS1 1L ROS1+
5. #HARMONi 2L mEGFR
SCLC
6. #MAVERICK @SWOG MRI surv
7. #DeLLphi Tarla SubQ & ⬇️ freq
#lcsm #OncTwitter @IASLC
1/8
Dawood Findakly, MD, FACP retweeted
🚨New @US_FDA approval based off the #HERIZON-GEA-01 study analyzing #Zanidatamab in first line #HER2 positive mGEA
#OncTwitter #Oncology #gcsm #MedTwitter #MedX #HemOnc #FDA
Based off HERIZON-GEA-01, #Zanidatamab is now @US_FDA ✅ in 1L HER2+ mGEA:
⭐️PhIII, Zanidatamab + Chemo ± Tislelizumab vs. Trastuzumab + Chemo
- mPFS w/ Zani (±Tisle) 12.4 vs. 8.1mos
- mOS for triplet 26.4 vs. 19.2mos HR: 0.72
- ⬆️Diarrhea & Infusion reactions
#OncTwitter
Dawood Findakly, MD, FACP retweeted
Iberdomide (first CELMoD) now @US_FDA ✅ based off EXCALIBER-RRMM in 2L and beyond for R/R #MultipleMyeloma.
IberDd:
- Improved MRD (41% vs. 21%)
- PFS still immature
- AEs: Cytopenias and Infections
#OncTwitter #MedTwitter #HemeTwitter
Dawood Findakly, MD, FACP retweeted
Still trying to figure out how to adopt the data from OPTIMA trial in my practice (and how to use OncotypeDx vs. PAM50 scoring/test). Who is the right patient? Should I pivot completely from other tests and just rely on PAM50?
@ErikaHamilton9 @PTarantinoMD @hoperugo @DrSGraff
Dawood Findakly, MD, FACP retweeted
Here are the options we had a chance to touch on with @myelomaMD and #MaxMerz during our discussions on Early and Late Relapse/Refractory #MultipleMyeloma
#OncTwitter #HemeTwitter @OncUpdates @OncoAlert
As we start to close the topic of #Myeloma, here is the treatment algorithm 🗣️ on Late Relapse/Refractory #MultipleMyeloma w/ #MaxMerz
✅ BsAbs
✅ ADCs
✅ Chemo
Full 🗣️:
⭐️ oncbrothers.com/late-rrmm-20…
⭐️ Also on “Oncology Brothers” podcast
#OncTwitter #HemeTwitter #mmsm
Dawood Findakly, MD, FACP retweeted
📣 FDA approval of Pluvicto triplet vs ADT/ARPI for mCSPC (APMS) #PSMAddition
✔️ rPFS: HR 0.72
✔️ time to mCRPC: HR 0.70
✔️ similar QoL
❓OS data immature
❗️ wide eligibility criteria for ➕ PSMA
❓vs chemo or other triplets (PARP/AKT)
Exciting year for GU onc!
Dawood Findakly, MD, FACP retweeted
Based off #ENDURANCE trial, Lenalidomide is now for 2yrs maintenance (instead of indefinite) for standard risk #MultipleMyeloma (75-80% of myeloma can fall in this category). Indefinite maintenance did NOT improve OS when compared to 2yrs therapy!
#HemeTwitter #OncTwitter
In our ongoing Multiple Myeloma series we had a chance to 🗣️ #ENDURANCE trial w/ @myelomaMD & @VincentRK
✅ New SoC duration for Maintenance
✅ Can we extrapolate to other pts?
Full 🗣️:
⭐️ oncbrothers.com/endurance-tr…
⭐️ “Oncology Brothers” podcast
#OncTwitter #HemeTwitter